Aller au contenu principal
Accès ouvert déclaré 2025 review

Early cancer diagnosis and community pharmacies: a systematic review

4Citations signalées, ce qui n’est pas une note de qualité
5Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : gb. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background Patients with symptoms of suspected cancer usually present to general practice; however, they may present to other healthcare providers, such as community pharmacies. The clinical role of pharmacy staff has significantly increased in England in recent years. Aim To describe the range of interventions targeting early cancer detection in community pharmacies globally; to summarise the outcomes of these interventions; to report on barriers and facilitators to delivering the interventions and on service users’ and stakeholders’ experiences with such interventions. Design and setting Systematic review with narrative synthesis, of international literature, on community pharmacy-based early cancer detection. Method Online searches of Medline, CINAHL, Cochrane CENTRAL, PsycINFO, and Embase and UK-based relevant grey literature were performed. Interventions were defined as any intervention, initiative, or programme that focused on community pharmacy-based early cancer detection programmes. Results In total, 14 134 titles and abstracts were screened, and 330 full-text publications were reviewed by two independent reviewers. Of these, 52 publications were included in the review. They reported on interventions focusing on early diagnosis of colorectal ( n = 19), skin ( n = 8), lung ( n = 4), cervical ( n = 3), breast ( n = 2), head and neck ( n = 2), and mixed ( n = 14) cancers. The feasibility and acceptability of such interventions by community pharmacy staff and customers/patients have been demonstrated in the included studies. Studies involving opportunistic identification of customers with suspected cancer symptoms in pharmacies recruited only a few participants. Conclusion Robust, large-scale clinical trials are needed to demonstrate cost-effectiveness, delineate and inform the use of relevant clinical outcomes, and to explore arrangements for information sharing between community pharmacy and other healthcare settings.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Early cancer diagnosis and community pharmacies: a systematic review
Date Crossref
15/09/2025
Éditeur
Royal College of General Practitioners
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Pharmaceutical Practices and Patient OutcomesGlobal Cancer Incidence and ScreeningAcute Lymphoblastic Leukemia research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.